Treatment of Asymptomatic H. pylori Infection

Clinical Context and Rationale

The European Helicobacter Study Group recommends a "test and treat" strategy for symptomatic dyspeptic patients under age 45 without alarm symptoms, but not for asymptomatic individuals who happen to test positive 3, 4, 5, 6.
The American Gastroenterological Association and the European Helicobacter Study Group suggest that H. pylori testing serves as a diagnostic tool to identify those likely to benefit from eradication therapy in patients presenting with dyspeptic symptoms in primary care 3, 5, 6.

The European Helicobacter Study Group and the American College of Gastroenterology recommend treating asymptomatic H. pylori-positive patients with a family history of gastric cancer, as this represents a significant risk factor that warrants eradication even without symptoms 3, 5, 2.
The American College of Gastroenterology suggests that eradication reduces the risk of NSAID-induced peptic ulcer disease in patients planned for long-term NSAID therapy 7, 8.
The European Helicobacter Study Group recommends eradication for patients with a history of documented peptic ulcer disease, even if currently asymptomatic, as it prevents ulcer recurrence and eliminates peptic ulcer mortality risk 7, 6.
The American Gastroenterological Association and the European Helicobacter Study Group suggest that H. pylori eradication can lead to lymphoma regression in patients with low-grade gastric MALT lymphoma 6, 2.
The European Helicobacter Study Group recommends eradication for patients with severe gastric atrophy or intestinal metaplasia on prior endoscopy, as these represent premalignant conditions where eradication may reduce gastric cancer risk 6.

The American College of Gastroenterology and the European Helicobacter Study Group recommend determining why the H. pylori test was ordered and screening for high-risk conditions, such as family history of gastric cancer, prior peptic ulcer disease, chronic NSAID use, and any history of gastric pathology, before making treatment decisions 3, 5, 2.
The European Helicobacter Study Group suggests that if no high-risk features are present, observation is appropriate, and the patient should be counseled that H. pylori causes chronic gastritis but most infected individuals never develop complications 7, 4.

The American Gastroenterological Association and the European Helicobacter Study Group emphasize that the guidelines support treating H. pylori in the context of clinical presentations, not as a screening program for asymptomatic populations, and that cost-effectiveness analyses were performed in symptomatic dyspeptic patients, not in screening asymptomatic individuals 3, 6, 5, 4.
The European Helicobacter Study Group and the American College of Gastroenterology warn that widespread unnecessary eradication therapy contributes to antibiotic resistance, and this risk must be weighed against benefits, which are minimal in truly asymptomatic patients without high-risk features 5, 2.
The American College of Gastroenterology recommends that serology cannot distinguish active infection from past exposure, so if an asymptomatic patient has a positive serological test, consider confirming with urea breath test or stool antigen test before making treatment decisions 2.